ESMO 2022 | Clinical & tumor characteristics of patients with recurrent melanoma upon immunotherapy

Judith Versluis, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses clinical features of acquired resistance in stage IV melanoma patients treated with immune checkpoint inhibition. 142 patients who achieved a pathological response and subsequently relapsed from the OpACIN (NCT02437279), OpACIN-neo (NCT02977052) and PRADO (NCT02977052) trials were assessed, where ipilimumab and nivolumab were administered. Despite a small sample of tumors, an increase or decease of immune cells was observed depending on location of metastases. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.